The Global Insomnia Market, encompassing both pharmaceutical and non-pharmaceutical solutions for the treatment of insomnia, is projected to reach a valuation of US$ 7.5 billion by 2030. This growth is driven by a compound annual growth rate (CAGR) of 11.2% during the forecast period of 2024 to 2031.

The market caters to the increasing demand for effective treatments for insomnia, a sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early and not being able to go back to sleep.

The insomnia market is primarily driven by the increasing prevalence of the condition, fueled by factors such as stress, anxiety, and unhealthy lifestyles. Additionally, the growing aging population, which is more susceptible to sleep disorders, is expected to contribute significantly to market growth. Companies operating in this market are actively investing in research and development to introduce novel insomnia drugs with improved safety and efficacy profiles, addressing the limitations of existing treatments.

The Global Insomnia Market is witnessing a surge in demand for innovative solutions, driven by the rising awareness of the impact of insomnia on overall health and well-being. Market dynamics are shaped by the development of novel therapies, the adoption of digital therapeutics, and the integration of wearable devices for sleep monitoring. These technological advancements offer personalized interventions, real-time data collection, and enhanced treatment approaches. Moreover, the expansion of the market into emerging economies, coupled with collaborations and partnerships between pharmaceutical companies, research institutions, and technology firms, presents significant growth opportunities.

Insomnia is a sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early and not being able to go back to sleep. It can lead to fatigue, irritability, and difficulty concentrating during the day. Insomnia can be acute (short-term) or chronic (long-term). It can be caused by various factors, including stress, anxiety, depression, medical conditions, and lifestyle factors.

Treatment for insomnia may include cognitive-behavioral therapy, medication (e.g., sedatives, hypnotics), and lifestyle changes (e.g., exercise, stress management, sleep hygiene).

Key Report Insights:

• Major market driver: Increasing prevalence of insomnia due to factors such as stress, anxiety, and lifestyle changes. According to the American Sleep Association, around 30% of adults report having symptoms of insomnia.
• Companies are investing in research and development of new insomnia medications with improved safety and efficacy profiles. Examples include Idorsia's daridorexant, Eisai's lemborexant, and Minerva Neurosciences' MIN-202.
• Advancements in diagnostics include wearable devices and apps that track sleep patterns and help identify insomnia.
• A potential major technological shift could be the development of digital therapeutics or mobile apps that provide cognitive-behavioral therapy for insomnia.

Drivers:

• Increasing Prevalence of Insomnia: According to the American Sleep Association, around 30% of adults report having symptoms of insomnia, driving the demand for effective treatments and management strategies.
• Rising Stress and Anxiety Levels: Factors such as work-related stress, personal life challenges, and mental health conditions like anxiety and depression are contributing to the increasing prevalence of insomnia, fueling market growth.

Trends:

• Emphasis on Non-Pharmacological Therapies: There is a growing trend towards exploring and adopting non-pharmacological therapies for insomnia management, such as cognitive-behavioral therapy and relaxation techniques.
• Integration of Wearable Devices and Sleep Monitoring: The integration of wearable devices and sleep monitoring technologies is becoming a prominent trend in the Insomnia Market, enabling personalized interventions and real-time monitoring.

Market Opportunity:

The rapid advancement of digital therapeutics and mobile health presents a significant opportunity for the Insomnia Market.

Key Regional Insights:

• North America is expected to be the largest market for the Global Insomnia Market, accounting for over 35.8% of the market share in 2023. Prominent companies like Merck & Co., Pfizer Inc., and Vanda Pharmaceuticals Inc. have a strong presence in this region. The high prevalence of insomnia, the presence of major pharmaceutical companies, and the availability of advanced healthcare infrastructure are driving the market growth in North America.
• Europe is expected to be the second-largest market for the Global Insomnia Market, accounting for over 28.6% of the market share in 2023. Companies such as Sanofi, Idorsia Pharmaceuticals Ltd., and Takeda Pharmaceutical Company Limited have a significant presence in this region. The increasing aging population and rising awareness about insomnia and its management are contributing to the market growth in Europe.
• Prominent companies present in the Global Insomnia Market include Sanofi, Merck & Co., Pfizer Inc., Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Idorsia Pharmaceuticals Ltd., Minerva Neurosciences, Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Ltd., and Lundbeck.

Market Segmentation:

• By Product Type
  • Prescription sleep medications
  • Over-the-counter sleep aids
  • Medical devices (e.g., CPAP machines)
  • Others (herbal supplements, melatonin)
• By Insomnia Type
  • Chronic insomnia
  • Acute insomnia
  • Comorbid insomnia
  • Others (paradoxical insomnia, idiopathic insomnia)
• By Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Others (clinics, sleep centers)
• By Treatment
  • Pharmacological treatments
  • Non-pharmacological treatments (e.g., CBT, relaxation techniques)
  • Others (light therapy, acupuncture)
• By End User
  • Hospitals
  • Sleep centers
  • Clinics
  • Home care settings
  • Others (nursing homes, assisted living facilities)
• By Cause
  • Medical conditions (e.g., chronic pain, cancer)
  • Psychiatric disorders (e.g., anxiety, depression)
  • Substance abuse
  • Lifestyle factors (e.g., stress, jet lag)
  • Hormonal imbalances
  • Others (medications, environmental factors)
• By Age Group
  • Pediatric insomnia
  • Adult insomnia
  • Geriatric insomnia
• By Regions
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Definition:

“The Global Insomnia Market refers to the industry that encompasses the development, manufacturing, and distribution of various products and services for the treatment and management of insomnia, a sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early and not being able to go back to sleep. This market includes prescription sleep medications, over-the-counter sleep aids, medical devices (e.g., CPAP machines), non-pharmacological treatments like cognitive-behavioral therapy, and digital solutions for sleep monitoring and management. The market aims to provide effective and safe solutions to address the challenges faced by individuals suffering from insomnia, which can lead to fatigue, irritability, and difficulty concentrating during the day if left untreated.”